GNI Group Ltd
TSE:2160

Watchlist Manager
GNI Group Ltd Logo
GNI Group Ltd
TSE:2160
Watchlist
Price: 3 380 JPY 5.13% Market Closed
Market Cap: 169.4B JPY
Have any thoughts about
GNI Group Ltd?
Write Note

Gross Margin
GNI Group Ltd

79.1%
Current
85%
Average
63.9%
Industry

Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.

Gross Margin
79.1%
=
Gross Profit
17.9B
/
Revenue
22.7B

Gross Margin Across Competitors

Country Company Market Cap Gross
Margin
JP
GNI Group Ltd
TSE:2160
169.2B JPY
79%
FR
Pharnext SCA
OTC:PNEXF
6T USD
0%
US
Abbvie Inc
NYSE:ABBV
311.8B USD
67%
US
Amgen Inc
NASDAQ:AMGN
140.7B USD
60%
US
Gilead Sciences Inc
NASDAQ:GILD
115.7B USD
78%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
102.7B USD
86%
US
Epizyme Inc
F:EPE
94.1B EUR
76%
AU
CSL Ltd
ASX:CSL
134.4B AUD
52%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
78B USD
87%
US
Seagen Inc
F:SGT
39.3B EUR
75%
NL
argenx SE
XBRU:ARGX
36B EUR
89%
Country JP
Market Cap 169.2B JPY
Gross Margin
79%
Country FR
Market Cap 6T USD
Gross Margin
0%
Country US
Market Cap 311.8B USD
Gross Margin
67%
Country US
Market Cap 140.7B USD
Gross Margin
60%
Country US
Market Cap 115.7B USD
Gross Margin
78%
Country US
Market Cap 102.7B USD
Gross Margin
86%
Country US
Market Cap 94.1B EUR
Gross Margin
76%
Country AU
Market Cap 134.4B AUD
Gross Margin
52%
Country US
Market Cap 78B USD
Gross Margin
87%
Country US
Market Cap 39.3B EUR
Gross Margin
75%
Country NL
Market Cap 36B EUR
Gross Margin
89%
No Stocks Found

GNI Group Ltd
Glance View

Market Cap
169.2B JPY
Industry
Biotechnology

GNI Group Ltd. engages in the development, research, manufacture, and sale of pharmaceutical drugs and traditional Chinese medicines. The company is headquartered in Chuo-Ku, Tokyo-To and currently employs 629 full-time employees. The company went IPO on 2007-08-31. The firm is engaged in the development of therapeutic agents for diseases that have many sufferers in Asian countries such as Japan and China, as well as clinical trial and bio-verification test businesses. The company is engaged in research and development of therapeutic agents, including F647 for radiation pneumonia (RP) and idiopathic pulmonary fibrosis (IPF), F351 for liver fibrosis (cirrhosis) and F573 for acute hepatic insufficiency and acute chronic liver failure (ACLF).

Intrinsic Value
4 956.28 JPY
Undervaluation 32%
Intrinsic Value
Price

See Also

Discover More
What is Gross Margin?

Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.

Gross Margin
79.1%
=
Gross Profit
17.9B
/
Revenue
22.7B
What is the Gross Margin of GNI Group Ltd?

Based on GNI Group Ltd's most recent financial statements, the company has Gross Margin of 79.1%.